0001567619-23-001927.txt : 20230206
0001567619-23-001927.hdr.sgml : 20230206
20230206164703
ACCESSION NUMBER: 0001567619-23-001927
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230202
FILED AS OF DATE: 20230206
DATE AS OF CHANGE: 20230206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ogden Christopher
CENTRAL INDEX KEY: 0001914523
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 23591277
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273521219
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2023-02-02
0
0001501989
CytomX Therapeutics, Inc.
CTMX
0001914523
Ogden Christopher
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
SVP, Finance and Accounting
Common Stock
2023-02-02
4
A
0
25000
0
A
38288
D
Stock Option (Right to Buy)
2.59
2023-02-02
4
A
0
75000
0.00
A
2033-02-01
Common Stock
75000
75000
D
Performance Stock Units (PSUs)
2023-02-02
4
A
0
75000
0.00
A
Common Stock
75000
75000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.
Includes 32,288 RSUs.
Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022.
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
2023-02-06